Quarterly report pursuant to Section 13 or 15(d)

Acquisitions, Investments and Licenses - Transition Therapeutics Purchase Price Allocation (Details)

v3.5.0.2
Acquisitions, Investments and Licenses - Transition Therapeutics Purchase Price Allocation (Details) - USD ($)
$ in Thousands
Sep. 30, 2016
Aug. 31, 2016
Dec. 31, 2015
Aug. 31, 2015
Business Acquisition [Line Items]        
Goodwill $ 700,526   $ 743,348  
Transition Therapeutics        
Business Acquisition [Line Items]        
Cash and cash equivalents       $ 15,878
Goodwill   $ 3,453    
Other assets   634    
Accounts payable and other liabilities   (1,035)    
Deferred tax liability   (1,400)    
Total purchase price   58,530    
In Process Research and Development | Transition Therapeutics        
Business Acquisition [Line Items]        
Intangible assets   $ 41,000